Skip to main content

Advertisement

Table 1 Clinicopathologic characteristics and overall survival information of 444 patients with gastric cancer who underwent gastrectomy

From: Prognostic value of systemic immune-inflammation index in patients with gastric cancer

Characteristic No. of patients (%) Mean OS with 95% CI (months) P valueb
Sex    0.170
 Man 281 (63.3) 54 (48–60)  
 Woman 163 (36.7) 61 (53–69)  
Age (years)    0.061
 <60 249 (56.1) 60 (53–66)  
 ≥60 195 (43.9) 53 (46–59)  
Tumor location    0.043
 Upper stomach 140 (31.5) 48 (40–56)  
 Middle stomach 137 (30.9) 58 (50–67)  
 Lower stomach 167 (37.6) 62 (54–70)  
Tumor size (cm)    <0.001
 <5 221 (49.8) 73 (66–80)  
 ≥5 223 (50.2) 40 (34–46)  
Pathologic type    0.330
 Adenocarcinoma 367 (82.7) 57 (52–62)  
 Squamous carcinoma 25 (5.6) 50 (28–71)  
 Adenosquamous carcinoma 3 (0.7) 37 (18–57)  
 Ring cell carcinoma 39 (8.8) 53 (36–69)  
 Undifferentiated carcinoma 10 (2.3) 86 (39–133)  
Borrmann classification    <0.001
 1 30 (6.8) 78 (55–102)  
 2 98 (22.1) 76 (66–85)  
 3 259 (58.3) 55 (49–61)  
 4 50 (11.3) 20 (12–29)  
 5 7 (1.6) 30 (3–55)  
pTa    <0.001
 1 53 (11.9) 99 (87–110)  
 2 41 (9.2) 89 (76–103)  
 3 175 (39.4) 59 (52–65)  
 4 175 (39.4) 34 (27–41)  
pNa    <0.001
 0 152 (34.2) 92 (85–100)  
 1 185 (41.7) 42 (36–48)  
 2 77 (17.3) 34 (25–43)  
 3 30 (6.8) 24 (12–37)  
pMa    <0.001
 0 337 (75.9) 67 (63–73)  
 1 107 (24.1) 21 (14–27)  
TNM stagea    <0.001
 I 77 (17.3) 101 (92–110)  
 II 64 (14.4) 79 (67–90)  
 III 196 (44.1) 52 (45–58)  
 IV 107 (24.1) 21 (14–27)  
CEA (μg/L)    0.023
 <5 399 (89.9) 59 (54–63)  
 ≥5 45 (10.1) 39 (26–53)  
NLR    0.510
 <2.10 205 (46.2) 65 (58–72)  
 ≥2.10 239 (53.8) 49 (43–56)  
PLR    0.201
 <120 144 (32.4) 67 (59–76)  
 ≥120 300 (67.6) 51 (46–57)  
SII    <0.001
 <660 283 (63.7) 65 (59–71)  
 ≥660 161 (36.3) 42 (35–49)  
  1. OS, overall survival; CI, confidence interval; CEA, carcinoembryonic antigen; NLR, neutrophil–lymphocyte ratio; PLR, platelet–lymphocyte ratio; SII, systemic immune-inflammation index
  2. aTumor stage was defined according to the 2010 American Joint Committee on Cancer (AJCC) TNM staging system
  3. bANOVA analysis was used to compare the OS